GYRE Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Gyre Therapeutics Inc (GYRE) appears to be a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company's strong financial growth in revenue, net income, and EPS, combined with bullish technical indicators, supports this decision. While there are no significant trading trends or recent news, the positive financial performance and stable technical outlook make it a solid choice for long-term investment.
The stock is showing bullish technical indicators. The MACD histogram is positive and contracting, suggesting upward momentum. The RSI is neutral at 63.88, and the moving averages are bullish (SMA_5 > SMA_20 > SMA_200). The stock is trading near its pivot level of 8.273, with resistance levels at 8.788 and 9.107, and support levels at 7.757 and 7.438.
The company's financial performance in Q3 2025 shows strong growth: revenue increased by 19.92% YoY, net income surged by 221.17% YoY, and EPS grew by 200% YoY. Additionally, the stock's bullish technical indicators support a positive outlook.
No significant trading trends from hedge funds or insiders. The gross margin dropped slightly by -1.63% YoY. There is also a lack of recent news or trend analysis, which limits visibility into short-term catalysts.
In Q3 2025, Gyre Therapeutics reported revenue of $30.56M, up 19.92% YoY. Net income increased to $3.61M, a 221.17% YoY growth. EPS rose to 0.03, up 200% YoY. However, the gross margin slightly declined to 94.67%, down -1.63% YoY.
No data available for analyst ratings or price target changes.
